Three IPOs, Three SPAC Mergers, But One Company Opted Out
Talaris, Valneva, Anebulo Make 43 US Biopharma IPOs In 2021
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
You may also be interested in...
Fresh cash will help advance the UK firm's one-time investigational gene therapy for geographic atrophy and a listing in the US is in the offing.
The company is hoping for strong efficacy from its inactivated vaccine, boosted by two adjuvants
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.